Second Genome Incis A Clinical Stage Pharmaceutical Company Based In South San Franciscocaliforniaspecializing In Microbiome Sciencefounded In 2009The Company Focuses On Translating Microbial Genetics Into Precision Therapeutics And Biomarkers For Inflammatorymetabolicand Immune Related Diseases The Company Utilizes Its Proprietary Microbiome Discovery Platformwhich Integrates Computational Sciencemachine Learningand Human Disease Biology To Enhance Drug Discoverysecond Genome S Therapeutic Pipeline Includes Sg 2 0776A Microbiome Derived Therapeutic Protein Aimed At Mucosal Healing In Inflammatory Bowel Diseasecurrently In Pre Clinical Studiesadditionallythe Company Develops Precision Biomarkers To Help Stratify Patients And Monitor Therapeutic Responses Second Genome Collaborates With Partners In Healthcarenutritionand Agricultureworking To Advance Therapies For Serious Diseasesthe Company Is Recognized As A Great Place To Worka With A Strong Emphasis On Innovation And Talent Development Within Its Culture
